Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

3942 - The relationship between Naldemedine administration and the maximum dose of oral opioids


28 Sep 2019


Poster Display session 1


End-of-Life Care

Tumour Site


Shinya Kajiura


Annals of Oncology (2019) 30 (suppl_5): v661-v666. 10.1093/annonc/mdz261


S. Kajiura1, S. Chikaoka2, T. Yokota3, A. Kadota1, S. Fukai1, T. Matsushita1, N. Hayashi1, Y. Yagi1, N. Ryu1, H. Horikawa1, K. Takemura1, A. Furuichi1, K. Nakajima1, I. Moto3, S. Nanjyo3, H. Mihara3, T. Ando3, N. Murakami1, I. Yasuda3, R. Hayashi1

Author affiliations

  • 1 Clinical Oncology, Toyama University Hospital, 930-0194 - Toyama/JP
  • 2 Clinical Oncology, Toyama University Hospital, 9300194 - Toyama/JP
  • 3 Internal Medicine, Toyama University Hospital, 930-0194 - Toyama/JP


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 3942


Opioid-induced constipation (OIC) is the most common side effect of opioid therapy. Laxatives are usually used as a first-line treatment option for OIC. Treatment options for OIC are switching to other opioids associated with less frequent OIC, such as Fentanyl. Naldemedine is an orally active peripherally acting µ-opioid receptor antagonists that was approved in Japan from 2017 for management cancer-related OIC. The aim of this study is to investigate the relationship between Naldemedine administration and the maximum dose of oral Oxycodone which is the oral opioids used most at our hospital.


During June 2017 and December 2018, a total of 217 patients with cancer-related pain received Oxycodone at our institution. The first group of the patients concurrently received Naldemedine 0.2 mg daily (group A, n = 100) and the second group didn’t receive (group B, n = 117) for cancer-related OIC reduction. We compared the maximum Oxycodone dose between two groups by medical recode retrospectively.


The median age of group A was 69 y.o. (range 20-87 y.o.), and the median age of group B was 67 y.o. (range 27-88y.o.). There was no significant difference in common patient background between group A and B. The median dose of maximum Oxycodone dose of group A was 40 mg/day (range 10-480 mg/day), and the median dose of maximum Oxycodone dose of group B was 20 mg/day (range 10-320 mg/day). There was a significant difference (Mann-Whitney U test, P < 0.0001).


Naldemedine administration in patients with cancer-related OIC may increase the maximum dose of oral Oxycodone.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.